Company news

Kura Oncology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

November 1, 2023

Kura Oncology to Participate in Three Upcoming Investor Conferences

October 29, 2023

Kura Oncology to Report Third Quarter 2023 Financial Results

October 25, 2023

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

October 18, 2023

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

October 16, 2023

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 3, 2023

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

September 27, 2023

Kura Oncology to Participate in Cantor Global Healthcare Conference 2023

September 18, 2023

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

August 13, 2023

Kura Oncology Reports Second Quarter 2023 Financial Results

August 2, 2023

Kura Oncology to Report Second Quarter 2023 Financial Results

July 26, 2023

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

June 13, 2023

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

June 12, 2023

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

June 10, 2023

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

May 29, 2023

Kura Oncology to Participate in Two Upcoming Investor Conferences

May 22, 2023

Kura Oncology Reports First Quarter 2023 Financial Results

May 9, 2023

Kura Oncology to Participate in JMP Securities Life Sciences Conference

May 8, 2023

Kura Oncology to Report First Quarter 2023 Financial Results

May 2, 2023

Kura Oncology to Participate in Stifel Targeted Oncology Days

April 17, 2023

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

April 16, 2023

Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

March 13, 2023

Kura Oncology to Participate in Upcoming Investor Conferences

February 28, 2023

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

February 15, 2023

Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

February 8, 2023

Kura Oncology to Participate in SVB Securities Global Biopharma Conference

February 6, 2023

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor

January 23, 2023

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

December 9, 2022

Kura Oncology to Host Investor Event on December 10, 2022

November 30, 2022

Kura Oncology Reports Third Quarter 2022 Financial Results

November 2, 2022

Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting

November 2, 2022

Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

November 2, 2022

Kura Oncology to Report Third Quarter 2022 Financial Results

October 26, 2022

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

October 25, 2022

Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

August 31, 2022

Kura Oncology Reports Second Quarter 2022 Financial Results

August 2, 2022

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

August 1, 2022

Kura Oncology to Report Second Quarter 2022 Financial Results

July 26, 2022

Kura Oncology Reports First Quarter 2022 Financial Results

May 3, 2022

Kura Oncology to Report First Quarter 2022 Financial Results

April 26, 2022

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

April 7, 2022

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting

March 7, 2022

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

February 16, 2022

Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

February 9, 2022

Kura Oncology Expands Leadership Team with Key Promotions

January 31, 2022

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

January 19, 2022

Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

December 15, 2021

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax

December 12, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 54 decks. Every deck is listed under its year.